Baird analyst Michael Ha lowered the firm’s price target on Universal Health (UHS) to $204 from $241 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Universal Health downgraded to Market Perform from Outperform at Raymond James
- Universal Health Services Earnings Call Highlights Growth
- Universal Health Maintained at Hold as Q1 Beat Driven by Pricing Strength but Volume Trends Remain Soft
- Analyst Reiterates Sell on Universal Health as Policy Risks Offset Q1 Beat; Price Target Maintained at $215
- Universal Health price target lowered to $238 from $268 at Barclays